More Long Options

Viiv is promoting findings for their long acting PrEP & HIV meds.  They promote data that supports the efficacy of & preference for their long acting meds; Apretude, Vocabria & Cabenuva.  These injections aren't as long acting as Gilead's Lenacapavir.  There may be other reasons to prefer Viiv's options.

The company has also pledged to let some low income countries manufacture & market generic versions of these meds.  Making these drugs far more affordable.  This & Gilead's similar pledge were most likely due to public pressure & the US ceasing funding to HIV programs.

That's all for now, take care.

Cya...

High & Low Point Uggh...

 

I have an article & some crappy news.  I'll start with the article.  GlaxoSmithKline & ViiV Healthcare are have released a long acting injection of of Cabotegravir, sold as Cabenuva.  This news has been out for a bit.  It's a bimonthly injection given at the doctor's office for treating HIV.  They're currently working to extend the time between doses.  However, the news is that they're trying to have this medication be something that is self administered at home every 3 months.  They'd like to see that by the end of the decade.   This is doable.  The base meds are there.  With a little improvement & using current at home injection pens, this could happen.

On to the crap news.  At this moment, I no longer have a primary care physician.  I called to confirm my upcoming Monday appointment (it was the Wednesday before) & was told he had taken medical leave, retired & was not coming back into the office.  Now, I'm scrambling to find a new doctor.  It will probably be a nurse practitioner since there are very few actual doctors left in my area.  I have some ideas, but I'm not sure at this time.  I didn't need this stress.

That's my life at the moment.  More stress & another long term relationship ending without so much as a good bye.  

Hope things are better for everyone else.

Cya...

Long Run Efficacy...

 

This article is about ViiV's study of their long acting injected HIV medication, Cabenuva vs the daily Biktarvy.    The injected med is a dual & the other is a daily, oral, triple ingredient medication.   While I think this should've been done before going to market, at least it's being done now.

A point of concern is how much this research will include women in the study.  The article uses the word, "women," multiple times.  Most of the references are directly & actively referring to transgender women.  Only the most indirect statement just used "women".   HIV pharmaceutical research has been notably horrible about it's lack of inclusion of women in the studies.

We'll have to wait for the outcome.

Take care.

Cya...

FDA Approved...

 

I blogged the European Union approved a long acting injectable med for HIV  based on cabotegravir & rilpivirine.  The injection, Cabenuva is given monthly.   An oral regimen will proceed it for a month & is marketed as, Vocabria.  ViiV Healthcare is researching how to extend the time between injections.  The FDA recently approved this med.

 Taken from the piece.

The most common adverse reactions ... were injection site reactions, fever (pyrexia), fatigue, headache, musculoskeletal pain, nausea, sleep disorders, dizziness and rash. 

I'll try to keep up with this.  Take care

Cya...